01:46 AM EDT, 10/22/2026 (MT Newswires) -- Sartorius Stedim Biotech (DIM.PA) reiterated its guidance for growth in sales revenue for full-year 2026. The Paris-listed biopharmaceutical group continues to expect a 6% to 10% increase in sales revenue for the year in constant currencies. Excluding tariff-related effects, the company expects operational growth to be at the midpoint of the range.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.